Cakit 2007.

Methods	Parallel group design. Method of randomisation not stated. Method of analysis not described. Treated as outpatients for an unspecified time over 8 weeks (30‐minute sessions). Assessed at baseline and immediately after treatment. Assessors were blinded.
Participants	27 participants in the treadmill group and 27 in the control group. 6 dropouts in the treadmill group, 17 dropouts in the control group. No baseline characteristics given for dropouts. Participants' mean age 71.8 years; male/female 16/15. The Hoehn and Yahr scores were not given. The mean duration of PD was 5.6 years. Inclusion criteria: Parkinson's disease patients who fulfilled the UK Parkinson's Disease Society Brain Bank Criteria, were medically stable, were able to walk 10‐metre distance at least 3 times with or without assistive device, able to provide informed consent. Exclusion criteria: participants who had neurological conditions other than idiopathic Parkinson's disease, scored greater than 3 in Hoehn and Yahr, scored less than 20 in MMSE, postural hypotension, cardiovascular disorders, class C or D exercise risk by the American College of Sports Medicine (ACSM) criteria, musculoskeletal disorders, visual disturbance or vestibular dysfunction limiting locomotion or balance.
Interventions	Treadmill: 8‐Week exercise program using incremental speed‐dependent treadmill training. Programme comprised stretching, range of motion exercise, and treadmill training. The treadmill session lasted for 30 minutes and participants were observed during treadmill training by a physiatrist, who gave no assistance in the actual performance of the movements. Maximum tolerated walking speed was determined before the training session began. This speed then was halved and was used for a 5‐minute warm‐up period. After the warm‐up period, the belt speed was increased by increments of 0.6 km/h every 5 minutes. When the belt speed was increased to the highest speed at which the participant could walk safely and without stumbling, this maximum‐achieved belt speed was maintained for 5 minutes and then was followed by 0.6‐km/h decrements. The participant maintained the rest of the treadmill session at this speed for 15 minutes. Control: no intervention. Drug therapy was constant during the trial.
Outcomes	Berg Balance Test. Dynamic Gait Index. Falls Efficacy Scale. Walking distance on treadmill. Tolerated maximum speed on treadmill (km/h). Examinations took place when participants were in the 'on' phase of medication.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Eligibility Criteria	Low risk
Randomisation Method	Unclear risk	Method of randomisation not stated.
Concealment of Allocation	Unclear risk	Method of randomisation not stated.
Similarity at Baseline	Unclear risk	Baseline data given overall, not split by treatment group.
Withdrawals Described	High risk	43% withdrawals.
Intention To Treat Analysis	Unclear risk	Method of analysis not described.
Cointerventions Constant	Low risk	Drug therapy was constant during the trial.
Blinded Assessors	Low risk	Assessors were blinded to group allocation.